Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity therapies, having aired an ad in 2024 that urged people not to use them for ...

Copycat drugs can save consumers money in the short term. But the societal cost of the signals this sends to the pharmaceutical industry could be devastating. It will surely cause delays and defunding ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Eli Lilly lowered Zepbound’s starter dose to $349 per month The lower prices are available for uninsured patients and folks ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

New FDA rules will end some Long Islanders' access to low-cost alternatives to the pricey weight-loss drugs Zepbound and ...